Isthmus Partners LLC Has $414,000 Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Isthmus Partners LLC increased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,359 shares of the specialty pharmaceutical company’s stock after purchasing an additional 157 shares during the period. Isthmus Partners LLC’s holdings in Jazz Pharmaceuticals were worth $414,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in JAZZ. IFP Advisors Inc bought a new position in Jazz Pharmaceuticals during the 4th quarter worth $25,000. Jones Financial Companies Lllp increased its stake in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after acquiring an additional 130 shares during the period. UMB Bank n.a. increased its stake in Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 129 shares during the period. Lindbrook Capital LLC increased its stake in Jazz Pharmaceuticals by 82.6% during the 4th quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 176 shares during the period. Finally, Itau Unibanco Holding S.A. increased its stake in Jazz Pharmaceuticals by 63.2% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after acquiring an additional 172 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have commented on the company. HC Wainwright raised their price objective on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research note on Monday. Morgan Stanley reiterated an “overweight” rating and issued a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday. Royal Bank of Canada decreased their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $190.53.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the transaction, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now directly owns 439,744 shares in the company, valued at $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,193 shares of company stock valued at $3,533,122. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Trading Down 1.0 %

Shares of JAZZ stock opened at $137.45 on Tuesday. The firm has a market capitalization of $8.35 billion, a P/E ratio of 19.36, a P/E/G ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock’s fifty day simple moving average is $128.43 and its 200 day simple moving average is $120.23.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.